At a Glance
| Item | Detail |
|---|---|
| CDL / PMB Status | Chronic Disease List (CDL) condition; PMB 902T (psychiatric) |
| ICD-10 Codes | F31.0–F31.9 |
| SA Prevalence | ~2% (~1.0–1.2 million people) |
| Annual Cost (managed outpatient) | R5,400–R18,000 |
| Annual Cost (including hospitalisation) | R18,000–R50,000+ |
| Biologic Risk | No |
| Gap Cover Relevance | High |
What is Bipolar Disorder?
Bipolar disorder is a chronic mental health condition characterised by episodes of mania or hypomania (abnormally elevated mood, energy, and activity) alternating with episodes of depression. It is distinct from unipolar depression — the manic or hypomanic episodes are the defining feature, and they frequently go unrecognised, leading to an average diagnostic delay of 6–10 years in South Africa.
Bipolar I Disorder: Full manic episodes (lasting at least 7 days, or severe enough to require hospitalisation). Often includes psychotic features. Depression is common but not required for diagnosis.
Bipolar II Disorder: Hypomanic episodes (less severe than mania, no psychosis, no hospitalisation required) alternating with depressive episodes. Often misdiagnosed as depression. More common in women.
Cyclothymia: Chronic fluctuating mood with hypomanic and depressive symptoms, not meeting full criteria for Bipolar I or II. A milder but significant pattern.
Bipolar disorder carries a lifetime suicide risk of 15–20% — one of the highest of any psychiatric condition. This is the most important reason to establish robust psychiatric management and scheme coverage.
Bipolar disorder is a Chronic Disease List (CDL) condition. Approximately 1.0–1.2 million South Africans are affected.
Treatment
Bipolar disorder requires long-term pharmacological management. The goals are: stabilise acute episodes, prevent recurrence, and protect long-term cognitive and functional outcomes.
Mood Stabilisers — Maintenance Backbone
Lithium carbonate: The gold standard mood stabiliser for Bipolar I. Highly effective for both mania prevention and, to a lesser extent, bipolar depression. Requires serum level monitoring (therapeutic range 0.6–1.2 mmol/L). Narrow therapeutic index — toxicity occurs at levels only slightly above therapeutic. Monitoring: lithium levels quarterly initially, then 6-monthly when stable; renal function; thyroid function; EKG. ~R130/month generic.
Sodium valproate (divalproex): Effective for mania and mixed states. Also requires monitoring (LFTs, FBC, valproate levels). Teratogenic — avoid in women of childbearing potential or with strict contraception. ~R200/month generic.
Atypical Antipsychotics
Used for acute mania and increasingly for maintenance: - Quetiapine (generic): Highly effective for acute mania, bipolar depression, and maintenance. ~R600/month. - Olanzapine: Effective for acute mania. Monitor metabolic parameters (weight, glucose, lipids). ~R500/month generic. - Aripiprazole: Maintenance; better metabolic profile than olanzapine. ~R900/month generic.
Bipolar Depression — Specific Agents
Bipolar depression is notoriously undertreated. Standard antidepressants used alone can trigger mania or rapid cycling and are generally not used as monotherapy. - Lamotrigine: First-choice for bipolar depression prevention. Must be titrated slowly (Stevens-Johnson syndrome risk if titrated too fast). ~R450/month generic. - Quetiapine: Also approved for bipolar depression as a licensed indication. - Lurasidone (Latuda): Newer agent with evidence specifically for bipolar depression. More expensive (~R2,200/month) and may not be on standard CDL formulary.
Medication Costs (2025/2026 — Prices Estimated; SAHPRA SEP Verification Pending)
| Medication | Class | Monthly Cost | Annual Cost |
|---|---|---|---|
| Lithium carbonate 400mg (generic) | Mood stabiliser | ~R130 | ~R1,560 |
| Sodium valproate 500mg (generic) | Mood stabiliser | ~R200 | ~R2,400 |
| Quetiapine 300mg (generic) | Atypical antipsychotic | ~R600 | ~R7,200 |
| Lamotrigine 200mg (generic) | Bipolar depression | ~R450 | ~R5,400 |
| Aripiprazole 15mg (generic) | Maintenance | ~R900 | ~R10,800 |
| Lurasidone 40mg (Latuda) | Bipolar depression (newer) | ~R2,200 | ~R26,400 |
Annual Cost Breakdown
| Category | Low Estimate | High Estimate |
|---|---|---|
| GP visits (4 per year) | R3,200 | R3,200 |
| Psychiatrist visits (4 per year) | R5,000 | R12,000 |
| Chronic medication | R1,560 | R26,400 |
| Monitoring (lithium levels, LFTs, TFTs, metabolic) | R3,000 | R4,800 |
| Psychotherapy (clinical psychologist — optional) | R0 | R12,000 |
| Hospital (acute mania/crisis — moderate probability) | R0 | R50,000 |
| Total estimated annual cost | ~R12,760 | ~R83,000+ |
Medical Aid Coverage
Bipolar disorder is a CDL condition. Registered open medical aid schemes must fund: - Mood stabilisers (lithium, valproate) at CDL formulary level - Atypical antipsychotics (quetiapine, olanzapine) — CDL formulary coverage varies; verify per scheme - Psychiatrist consultations (specialist benefit) - Monitoring blood tests (lithium levels, LFTs, TFTs, metabolic panel) - Acute psychiatric hospitalisation (both voluntary and involuntary under the Mental Health Care Act)
Formulary gaps: Lamotrigine and lurasidone may require exceptional needs motivation on some CDL formularies. Quetiapine is widely available; aripiprazole varies.
Psychiatric hospitalisation: Private psychiatric facilities frequently charge above scheme rate. Psychiatrist specialist shortfall during hospitalisation is the primary financial exposure.
Gap Cover Relevance
High. The defining financial events for bipolar disorder are acute psychiatric hospitalisations — typically for manic episodes or suicidal crises. Private psychiatric units charge for bed, treating psychiatrist, and allied health (occupational therapist, clinical psychologist) separately.
Gap cover addresses: - Psychiatrist shortfall during admission (daily visits above scheme rate) - Facility co-payment if scheme applies one - Clinical psychologist shortfall if covered under gap policy
Gap cover OPL ~R220,000 per year. Prolonged psychiatric admissions (4–6 weeks) may involve significant shortfall accumulation. Patients with bipolar I who have frequent hospitalisations should assess whether their gap cover OPL is sufficient.
Key Considerations for Plan Selection
- Scheme mental health programme quality — does the scheme have a dedicated psychiatric managed care programme with case management?
- Psychiatric hospitalisation benefit — both voluntary and involuntary (Mental Health Care Act) admission coverage
- CDL formulary for atypical antipsychotics — quetiapine, aripiprazole, and lamotrigine on formulary without exceptional needs
- Psychiatrist network depth — access to psychiatrists at scheme rate, not just any registered psychiatrist
- Lithium monitoring blood test benefit — quarterly levels required; some entry-level plans limit blood test frequency
What the PMB covers, in the regulation’s terms
- For major depression and bipolar disorder, the PMB is up to 3 weeks (21 days) a year of hospital-based care, including electroconvulsive therapy (ECT), or up to 15 outpatient therapy sessions instead of an admission. It is one or the other, never both. (902T. Medical Schemes Act regulations, Annexure A; outpatient alternative from the CMS PMB guideline (v1, 30.09.2020).)
Sources
- South African Society of Psychiatrists (SASOP) — Bipolar Disorder Guidelines 2022
- Bipolar SA — www.bipolarsa.co.za
- CMS PMB Regulation 8 — CDL: Bipolar Disorder
- SAHPRA SEP database — prices estimated; verification pending.
To see what your own plan pays, check your cover with AURA →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).